SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Middle East shipping and energy-infrastructure attack concerns are driving crude higher and drawing attention to USO, which tracks WTI futures. Traders are split between bullish supply-disruption fears and bearish calls for a pullback if tensions ease, with some warning the rally is stretched.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO decline is drawing attention, with traders focused on successive share-lockup expirations and reported insider selling as potential sources of supply, alongside a price-target cut and weakness in AI stocks. Bears see continued pressure from valuation and execution concerns, while bulls argue the selloff is overdone and point to the companys AI-chip technology and long-term potential.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is centered on concerns about its debt-heavy expansion and costly financing, with HSBCs bearish assessment adding to worries that AI demand may not translate into adequate returns. Traders are split between viewing the backlog and ongoing AI demand as a buying opportunity and fearing that credit costs and refinancing needs could constrain growth; a Goldman upgrade has not settled the debate.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

A steep selloff in USAR and the broader rare-earth sector is driving discussion, with traders pointing to dilution concerns, heavy spending before large-scale production and weak sentiment around management. Some blame short selling or broader market pressure, while bulls argue the companys government backing and domestic magnet ambitions support its long-term case and see the decline as oversold.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

UBSs downgrade of NuScale to Sell, citing long commercialization timelines and a lack of firm customer commitments, is driving the selloff. Traders debate whether it signals deeper execution risks, including delays around the TVA opportunity, or overstates the concerns amid weakness across nuclear stocks; some view the decline as a buying opportunity.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors Q3 results are driving discussion, with traders emphasizing strong revenue growth and improved margins while debating the GAAP EPS shortfall and the lack of forward guidance. Some view the AI power-delivery and licensing growth as encouraging, while others are cautious about valuation and whether the earnings news is enough to support the stock.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops warrant-expiration notice is driving discussion, as traders debate whether the approaching deadline and possible dilution are weighing on shares or whether unexercised warrants would remove dilution risk. Sentiment is split between frustration with Ryan Cohen and speculation about an extension or other corporate action; those hopes remain unconfirmed.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat and new multiyear buyback are drawing attention, but shares are falling as traders question why the stock dropped despite the results. The debate centers on the unchanged profit-outlook midpoint and weaker vehicle sales versus the buyback and stronger cash-flow outlook.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp AI-infrastructure selloff, as traders debate neocloud funding risks and Gartners warning that many providers may face consolidation. The community is split between viewing the recent bounce as an oversold relief move and expecting further weakness; bulls argue Nebius may be better positioned than debt-heavy peers and could benefit if demand shifts.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTXs quarterly results beat expectations and the company raised its full-year outlook, with growth across its aerospace and defense businesses and a record backlog. Traders largely describe the report as a broad-based beat, though some question why the share price has not responded more positively.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long

Equity

The FDA has told Novo that its review of the biologics license application is still underway and has not given a new date for a decision.

NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip

NVO stock is down 11% this week, on track for its worst week since late February if losses hold. 


NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen 

The Committee for Medicinal Products for Human Use recommended European Union marketing authorization for Frehemgo in adults and children with haemophilia A on Thursday.


AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus 

A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said. 


Want to Tap Global Growth? These Equity ETFs Could Benefit

Seeking growth beyond U.S. borders? Global equity ETFs could offer diversification and exposure to attractive opportunities across international markets.

NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future

Novo now expects underlying sales and operating profit in the range of 0% to –6% for the year.

NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court

The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.


Global ETFs to Diversify as Tech Weakness Weighs on Markets

The AI trade is under pressure as a semiconductor slump and financing concerns rattle markets, making global ETFs worth a closer look.

NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart

Oral Wegovy is now cleared in all EU member states.


Global ETFs Back in the Spotlight on Macroeconomic Tailwinds

Easing geopolitical tensions, a softer dollar and improving risk appetite are reviving interest in global equity ETFs.

American Century ETF Trust - Avantis International Equity ETF

Bullish Sentiment

<ul class="summary-bullets"><li>Novo said the agency extended the review because remediation at the facility is still ongoing.</li><li>The company said the longer review does not change its 2026 financial outlook.</li><li>Novo’s rare blood-disorders sales were about DKK 12.0 billion in 2025, against group sales of DKK 309 billion.</li></ul><p>Danish drugmaker Novo Nordisk (NVO) said on Friday that U.S. approval of its haemophilia A drug denecimig will slip past the third quarter because fixes at a manufacturing site are still underway.&nbsp;</p><p>The FDA has told Novo that its review of the biologics license application is still underway and has not provided a new decision date. Novo filed the application in September 2025 for adults and children with haemophilia A, with or without inhibitors, and had expected a ruling in the third quarter of 2026.</p><h2 class="st-heading-2">A Plant Issue, Not A Clinical One, Says Novo</h2><p>The delay follows a pre-license inspection of the manufacturing site. Novo said the agency extended the review because remediation at the facility is still ongoing. The company said it is already addressing the requests and working with the FDA on the remaining items. It also said the inspection feedback does not affect other marketed Novo products, and that the agency has not flagged deficiencies in the clinical efficacy or safety data in the filing.</p><p>Novo said the longer review does not change its 2026 financial outlook. It now aims to launch denecimig in the United States in the first half of 2027, pending a decision.</p><p>Novo’s rare blood-disorders sales were about DKK 12.0 billion in 2025, against group sales of DKK 309 billion. Obesity care alone was DKK 82 billion. Outside analysts have put denecimig’s peak sales near $2 billion a year. Roche’s Hemlibra, the drug it would have to take share from, did about $5.8 billion last year.</p><h2 class="st-heading-2">What The Drug Is Meant To Do</h2><p>Denecimig is a bispecific antibody designed to mimic factor VIIIa, the clotting protein missing or defective in haemophilia A.&nbsp; Novo is seeking approval for prophylaxis — treatment meant to prevent bleeds — on a monthly, every-two-week, or weekly schedule, including in patients who have developed inhibitors to standard factor replacement.</p><p>The filing rests on the FRONTIER program. FRONTIER2 tested weekly and monthly dosing in adults and adolescents 12 and older. FRONTIER3 did the same in children under 12. FRONTIER4, an open-label extension, looked at every-two-week dosing and longer-term safety across all three schedules.&nbsp;</p><p>On Sept. 17, denecimig received a positive opinion from the European Medicines Agency’s human medicines committee and is now also awaiting a European Commission decision.</p><h2 class="st-heading-2">How Did NVO Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">NVO stock</a> stayed neutral over the past 24 hours, while message volume remained low.&nbsp;</p><p>NVO stock has fallen 27% year-to-date.&nbsp;</p><p>Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-climbs-as-three-thursday-launches-meet-start-of-google-s-920-million-ai-pact/cZDjn9cRBKN">SPCX Stock Climbs As Three Thursday Launches Meet Start Of Google’s $920 Million AI Pact</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk A/S

VanEck Pharmaceutical ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$89.50
Prev Close	$90.07
Open	$89.93
Dividend Yield	N/A
50-Day Moving Average	$92.18
Beta	N/A
Avg. Volume	1.2M
PE Ratio	N/A

52-Week High	$94.82
52-Week Low	$77.20
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

AVDE Fundamentals